One of the world’s foremost interventional radiologists shares his views on the current state of endovascular therapy.
By Barry T. Katzen, MD
Restenosis continues to complicate percutaneous procedures, but new treatments hold promise.
By Robert S. Dieter, MD, RVT, and John R. Laird, Jr, MD
Excimer laser-assisted recanalization of SFA in-stent restenosis simplifies reintervention on restenosed stents and may prevent complications.
By Giancarlo Biamino, MD
Vascular brachytherapy still plays a role in the current treatment of restenosis.
By Ron Waksman, MD, FACC
Current and future applications of this technology show promising ability to resolve many of the troubling issues encountered in treating lower-extremity arterial disease.
By James D. Joye, DO
The application of a covered stent to treat nitinol stent restenosis in the SFA has so far proven to be a promising approach.
By Gary M. Ansel, MD; Charles F. Botti, Jr, MD; and Mitchell J. Silver, DO
Current clinical experience and future directions.
By Eberhard Grube, MD, and Lutz Buellesfeld, MD
How do factors such as in-stent restenosis impact the cost-effectiveness of angioplasty and stenting?
By Virginia Oliva, MD, and Ross Milner, MD
Use of a novel device for recurrent stenosis in the superficial femoral artery.
By Barry S. Weinstock, MD
Interviews and insights from some of the biggest hitters of all time!
By Paul Gianneschi
By John R. Laird, Jr, MD Chief Medical Editor
Adapting this coronary-based technology to optimize “functional” renal artery revascularization could have significant clinical implications.
By David E. Allie, MD; Chris J. Hebert, RT, RCIS; and Craig M. Walker, MD
Direct renal stenting has the potential to be as effective as stenting conducted by previous lesion dilatation.